Osteopore (ASX:OSX) Effective Interest Rate on Debt %: 7.18% (As of Dec. 2025)


What is Osteopore Effective Interest Rate on Debt %?

Osteopore ASX:OSX -20.00% Effective Interest Rate on Debt % is 7.18% as of Dec. 2025. The stock has 7 warning signs investors should review.

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Osteopore's annualized positive value of Interest Expense for the quarter that ended in Dec. 2025 was A$0.21 Mil. Osteopore's average total debt for the quarter that ended in Dec. 2025 was A$2.95 Mil. Therefore, Osteopore's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2025 was 7.18%.

Osteopore  (ASX:OSX) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Osteopore Effective Interest Rate on Debt % Related Terms

Osteopore Effective Interest Rate on Debt % Historical Data

* Premium members only.

The historical data trend for Osteopore's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Osteopore Effective Interest Rate on Debt % Chart

Osteopore Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Effective Interest Rate on Debt %
Get a 7-Day Free Trial 5.70 22.10 2.37 33.76 13.57

Osteopore Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.53 36.60 35.84 15.67 7.18

ASX:OSX vs ISRG, BDX, MDLN: Effective Interest Rate on Debt % Comparison

For the Medical Instruments & Supplies subindustry, Osteopore's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Osteopore Effective Interest Rate on Debt % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Osteopore's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Osteopore's Effective Interest Rate on Debt % falls into.


Osteopore Effective Interest Rate on Debt % Calculation

Osteopore's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2025 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2024 )+Total Debt  (A: Dec. 2025 ))/ count )
=-1  *  -0.28/( (1.331+2.795)/ 2 )
=-1  *  -0.28/2.063
=13.57 %

where

Total Debt  (A: Dec. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.11 + 1.221
=1.331

Total Debt  (A: Dec. 2025 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=1.452 + 1.343
=2.795

Osteopore's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2025 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Jun. 2025 )+Total Debt  (Q: Dec. 2025 ))/ count )
=-1  *  -0.212/( (3.11+2.795)/ 2 )
=-1  *  -0.212/2.9525
=7.18 %

where

Total Debt  (Q: Jun. 2025 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=1.613 + 1.497
=3.11

Total Debt  (Q: Dec. 2025 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=1.452 + 1.343
=2.795

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is two times the semi-annual (Dec. 2025) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

What does a Effective Interest Rate on Debt % of 7.18% mean?
Osteopore (ASX:OSX) has a Effective Interest Rate on Debt % of 7.18% as of Dec. 2025. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Osteopore and its competitors.
Is Osteopore's Effective Interest Rate on Debt % too high?
Osteopore's current Effective Interest Rate on Debt % is 7.18%.
How does Osteopore's Effective Interest Rate on Debt % compare to ISRG and BDX?
Osteopore's Effective Interest Rate on Debt % of 7.18% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Effective Interest Rate on Debt % for a Medical Devices & Instruments company?
A good Effective Interest Rate on Debt % depends on the Medical Devices & Instruments industry context. However, Effective Interest Rate on Debt % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Effective Interest Rate on Debt % mean?
A high Effective Interest Rate on Debt % can signal that a stock is expensive relative to its fundamentals. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Osteopore and its competitors. Osteopore's current Effective Interest Rate on Debt % is 7.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Osteopore stock overvalued right now?
Based on GuruFocus' analysis, Osteopore (ASX:OSX) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.00 — trading 80% below its estimated fair value. The current Effective Interest Rate on Debt % is 7.18%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Effective Interest Rate on Debt % calculated?
Effective Interest Rate on Debt % is calculated from a company's financial statements. For Osteopore (ASX:OSX), the current Effective Interest Rate on Debt % is 7.18% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Osteopore Business Description

Address 2 Tukang Innovation Grove, No. 09-06 and 07, JTC MedTech Hub, Singapore, SGP, 618305
Osteopore Ltd is engaged in the production of 3D-printed bioresorbable implants that are used in conjunction with surgical procedures to assist bone healing. Its products include Osteoplug, which is a bioresorbable implant used for covering trephination burr holes in neurosurgery, and Osteomesh which is a bioresorbable implant used in craniofacial surgery. It operate in the high-growth regenerative medicine sector, where adoption continues to rise as healthcare systems increasingly embrace developed tissue-regenerative solutions. Business operating segments are based on the firm's geographical presence in Singapore and Australia.